{
  "file_name": "CUAD_v1/full_contract_pdf\\Part_I\\Development\\EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.pdf",
  "annotations": [
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        }
      ],
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "ETON",
      "page_number": 0,
      "words": [
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        }
      ],
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Aucta",
      "page_number": 0,
      "words": [
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        }
      ],
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Aucta Pharmaceuticals, Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        }
      ],
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Eton Pharmaceuticals, Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        }
      ],
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "June 12, 2019",
      "page_number": 0,
      "words": [
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        }
      ],
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Effective Date_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effectiveÂ ",
      "answer_text": "The term of this Agreement shall automatically become effective upon the occurrence of (i) ETON executing a commercial supply agreement with a contract manufacturing organization within forty-five (45) days of the Execution Date, provided that ETON has exercised best efforts to execute such agreement and the failure to execute is solely caused by the refusal or inability of the proposed manufacturing organization to sign a reasonable agreement; and (ii) acceptance for review of the Dossier or marketing application for [ * * * ] by the FDA no later than September 2, 2019 (such date, the \"Effective Date\") and shall end upon the termination or expiration of the Agreement as set forth in Section 11 (the \"Term\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Effective Date_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effectiveÂ ",
      "answer_text": "The term of this Agreement shall automatically become effective upon the occurrence of (i) ETON executing a commercial supply agreement with a contract manufacturing organization within forty-five (45) days of the Execution Date, provided that ETON has exercised best efforts to execute such agreement and the failure to execute is solely caused by the refusal or inability of the proposed manufacturing organization to sign a reasonable agreement; and (ii) acceptance for review of the Dossier or marketing application for [ * * * ] by the FDA no later than September 2, 2019 (such date, the \"Effective Date\") and shall end upon the termination or expiration of the Agreement as set forth in Section 11 (the \"Term\").",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Expiration Date_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement shall automatically become effective upon the occurrence of (i) ETON executing a commercial supply agreement with a contract manufacturing organization within forty-five (45) days of the Execution Date, provided that ETON has exercised best efforts to execute such agreement and the failure to execute is solely caused by the refusal or inability of the proposed manufacturing organization to sign a reasonable agreement; and (ii) acceptance for review of the Dossier or marketing application for [ * * * ] by the FDA no later than September 2, 2019 (such date, the \"Effective Date\") and shall end upon the termination or expiration of the Agreement as set forth in Section 11 (the \"Term\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Expiration Date_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement shall automatically become effective upon the occurrence of (i) ETON executing a commercial supply agreement with a contract manufacturing organization within forty-five (45) days of the Execution Date, provided that ETON has exercised best efforts to execute such agreement and the failure to execute is solely caused by the refusal or inability of the proposed manufacturing organization to sign a reasonable agreement; and (ii) acceptance for review of the Dossier or marketing application for [ * * * ] by the FDA no later than September 2, 2019 (such date, the \"Effective Date\") and shall end upon the termination or expiration of the Agreement as set forth in Section 11 (the \"Term\").",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Governing Law_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement shall be governed, interpreted and construed in accordance with the substantive laws of the Delaware, in the country of the United State of America, without regard to its conflict of laws principles.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Governing Law_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement shall be governed, interpreted and construed in accordance with the substantive laws of the Delaware, in the country of the United State of America, without regard to its conflict of laws principles.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Non-Compete_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "During the Term of this Agreement, and for a period of two (2) years thereafter, Aucta shall not research, develop, manufacture, file, sell, market, or distribute more than two products containing the active ingredient Lamotrigine; nor will Aucta directly or indirectly assist any other Person or entity in carrying or any such activities. [ * * * ]",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Non-Compete_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "During the Term of this Agreement, and for a period of two (2) years thereafter, Aucta shall not research, develop, manufacture, file, sell, market, or distribute more than two products containing the active ingredient Lamotrigine; nor will Aucta directly or indirectly assist any other Person or entity in carrying or any such activities. [ * * * ]",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Aucta, for itself and its Affiliates, hereby grants to ETON in accordance with the terms and conditions of this Agreement, an exclusive (even as to and against Aucta in the Territory) right and license, including the right to sublicense, to the Products (or any components thereof), Dossiers, and all current and future Aucta Background Intellectual Property that is owned or controlled by Aucta or its Affiliates for ETON to develop, manufacture, import, use, promote, distribute, market, advertise, offer for sale or sell (collectively, \"Market\") the Products in and for the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Aucta, for itself and its Affiliates, hereby grants to ETON in accordance with the terms and conditions of this Agreement, an exclusive (even as to and against Aucta in the Territory) right and license, including the right to sublicense, to the Products (or any components thereof), Dossiers, and all current and future Aucta Background Intellectual Property that is owned or controlled by Aucta or its Affiliates for ETON to develop, manufacture, import, use, promote, distribute, market, advertise, offer for sale or sell (collectively, \"Market\") the Products in and for the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Termination For Convenience_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "ETON has the right to terminate this Agreement after approval of the Dossier or marketing application for the Product (or added new product), at its sole discretion, upon providing one hundred eighty (180) days' written notice to Aucta.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Termination For Convenience_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "ETON has the right to terminate this Agreement after approval of the Dossier or marketing application for the Product (or added new product), at its sole discretion, upon providing one hundred eighty (180) days' written notice to Aucta.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Change Of Control_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Notwithstanding the foregoing, each Party may assign the rights and obligations under this Agreement in whole, without consent of the other Party, to a Third Party or Affiliate in connection with the transfer or sale of all or substantially all of its business or in the event of a merger, consolidation or change in control provided that the assignee assumes in writing and becomes directly obligated to the other Party to perform all of the obligations of assignor under this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Change Of Control_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Notwithstanding the foregoing, each Party may assign the rights and obligations under this Agreement in whole, without consent of the other Party, to a Third Party or Affiliate in connection with the transfer or sale of all or substantially all of its business or in the event of a merger, consolidation or change in control provided that the assignee assumes in writing and becomes directly obligated to the other Party to perform all of the obligations of assignor under this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Anti-Assignment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "The Parties shall not assign, encumber or otherwise transfer this Agreement or any part of it to any Third Party, without the prior written consent of the other Party.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Revenue/Profit Sharing_0",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "ETON shall pay to Aucta a royalty payment of [ * * * ] of Net Sales of the Products.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Revenue/Profit Sharing_0",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Aucta should continue to receive 15% of Net Sales Royalty for as long as ETON is selling the Product(s) in the Territory, unless otherwise agreed to under this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Minimum Commitment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "If the amount of royalty payment under Section 6.3.1 is less than the amount of royalty payment under Section 6.3.2, then ETON shall pay Aucta the difference between royalty payments in Sections 6.3.1 and 6.3.2 within sixty (60) days of the calendar year end, but in no event shall the difference paid be greater than the minimum amount in Section 6.3.2.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Minimum Commitment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "If the amount of royalty payment under Section 6.3.1 is less than the amount of royalty payment under Section 6.3.2, then ETON shall pay Aucta the difference between royalty payments in Sections 6.3.1 and 6.3.2 within sixty (60) days of the calendar year end, but in no event shall the difference paid be greater than the minimum amount in Section 6.3.2.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Volume Restriction_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "During the Term of this Agreement, and for a period of two (2) years thereafter, Aucta shall not research, develop, manufacture, file, sell, market, or distribute more than two products containing the active ingredient Lamotrigine; nor will Aucta directly or indirectly assist any other Person or entity in carrying or any such activities.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Volume Restriction_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "During the Term of this Agreement, and for a period of two (2) years thereafter, Aucta shall not research, develop, manufacture, file, sell, market, or distribute more than two products containing the active ingredient Lamotrigine; nor will Aucta directly or indirectly assist any other Person or entity in carrying or any such activities.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Aucta, for itself and its Affiliates, hereby grants to ETON in accordance with the terms and conditions of this Agreement, an exclusive (even as to and against Aucta in the Territory) right and license, including the right to sublicense, to the Products (or any components thereof), Dossiers, and all current and future Aucta Background Intellectual Property that is owned or controlled by Aucta or its Affiliates for ETON to develop, manufacture, import, use, promote, distribute, market, advertise, offer for sale or sell (collectively, \"Market\") the Products in and for the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Aucta, for itself and its Affiliates, hereby grants to ETON in accordance with the terms and conditions of this Agreement, an exclusive (even as to and against Aucta in the Territory) right and license, including the right to sublicense, to the Products (or any components thereof), Dossiers, and all current and future Aucta Background Intellectual Property that is owned or controlled by Aucta or its Affiliates for ETON to develop, manufacture, import, use, promote, distribute, market, advertise, offer for sale or sell (collectively, \"Market\") the Products in and for the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "ETON, for itself and its Affiliates, hereby grants to Aucta in accordance with the terms and conditions of this Agreement, a right and license, to its trademark, including to its name and logo, that is owned or controlled by ETON or its Affiliates for Aucta (or its authorized Third Party) to make the packs, labels, and leaflets for the Products for sale in the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "ETON, for itself and its Affiliates, hereby grants to Aucta in accordance with the terms and conditions of this Agreement, a right and license, to its trademark, including to its name and logo, that is owned or controlled by ETON or its Affiliates for Aucta (or its authorized Third Party) to make the packs, labels, and leaflets for the Products for sale in the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In addition, within twenty-five (25) months after the termination or expiration of the Term and on a Product-by-Product basis, ETON shall perform a final \"true-up\" reconciliation and shall provide Aucta with a written report of such outlining the deductions specified in the definition of Net Sales.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Post-Termination Services_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In addition, within twenty-five (25) months after the termination or expiration of the Term and on a Product-by-Product basis, ETON shall perform a final \"true-up\" reconciliation and shall provide Aucta with a written report of such outlining the deductions specified in the definition of Net Sales.",
      "page_number": 2,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2701.0,
            256.0,
            3025.0,
            292.0
          ],
          "confidence": 0.9953160881996155
        },
        {
          "text": "1.16 \"GMP\"' means current good manufacturing practices as defined by the FDA..",
          "bbox": [
            448.0,
            311.0,
            1956.0,
            353.0
          ],
          "confidence": 0.9857128858566284
        },
        {
          "text": "1.17 \"Governmental Entity\"' means any arbitrator, court, judicial, legislative, administrative, or regulatory agency, commission, department,.",
          "bbox": [
            446.0,
            371.0,
            3029.0,
            418.0
          ],
          "confidence": 0.985506534576416
        },
        {
          "text": "board, or bureau or body or other government authority or instrumentality or any Person or entity exercising executive, legislative, judicial,",
          "bbox": [
            275.0,
            431.0,
            3027.0,
            475.0
          ],
          "confidence": 0.9825104475021362
        },
        {
          "text": "regulatory, or administrative functions of or pertaining to government, whether foreign or domestic, whether federal, state, provincial, municipal, or.",
          "bbox": [
            279.0,
            490.0,
            3029.0,
            534.0
          ],
          "confidence": 0.9963580965995789
        },
        {
          "text": "Other.",
          "bbox": [
            275.0,
            545.0,
            382.0,
            583.0
          ],
          "confidence": 0.9671776294708252
        },
        {
          "text": "1.18 \"Gross Sales\"' shall have the meaning ascribed to the term in Section 1.26.",
          "bbox": [
            446.0,
            598.0,
            1900.0,
            643.0
          ],
          "confidence": 0.989698052406311
        },
        {
          "text": "1.19 \"Indemnitee' shall have the meaning ascribed to the term in Section 13.3.1 of this Agreement..",
          "bbox": [
            446.0,
            658.0,
            2275.0,
            704.0
          ],
          "confidence": 0.9839974045753479
        },
        {
          "text": "1.20 \"Indemnitor' shall have the meaning ascribed to the term in Section 13.3.1 of this Agreement..",
          "bbox": [
            448.0,
            720.0,
            2275.0,
            762.0
          ],
          "confidence": 0.9868714213371277
        },
        {
          "text": "1.21 \"Infringement Notification Date\" shall have the meaning ascribed to the term in Section 7.4 of this Agreement..",
          "bbox": [
            448.0,
            780.0,
            2612.0,
            822.0
          ],
          "confidence": 0.9941144585609436
        },
        {
          "text": "1.22 \"Intellectual Rights Suit\" shall have the meaning ascribed to the term in Section 7.4 of this Agreement.",
          "bbox": [
            446.0,
            837.0,
            2461.0,
            883.0
          ],
          "confidence": 0.9914101958274841
        },
        {
          "text": "1.23 \"Losses\" means all losses, costs, damages, judgments, settlements, interest, fees or expenses including, without limitation, all.",
          "bbox": [
            444.0,
            894.0,
            3031.0,
            945.0
          ],
          "confidence": 0.9907868504524231
        },
        {
          "text": "reasonable attorneys' fees, experts' or consultants' fees, expenses and costs..",
          "bbox": [
            276.0,
            959.0,
            1711.0,
            1001.0
          ],
          "confidence": 0.9930619597434998
        },
        {
          "text": "1.24 \"Market' or \"Marketing\" shall have the meaning ascribed to the term in Section 2.1 of this Agreement.",
          "bbox": [
            446.0,
            1012.0,
            2456.0,
            1058.0
          ],
          "confidence": 0.9967002272605896
        },
        {
          "text": "1.25 \"NDC' means a national drug code as issued by the FDA..",
          "bbox": [
            446.0,
            1071.0,
            1615.0,
            1117.0
          ],
          "confidence": 0.9816356301307678
        },
        {
          "text": "1.26 \"Net Sales' means, with respect to each Product sold in the Territory, the aggregate gross sales amount invoiced by ETON or any.",
          "bbox": [
            442.0,
            1129.0,
            3029.0,
            1180.0
          ],
          "confidence": 0.9859305024147034
        },
        {
          "text": "sublicensee or other party authorized by ETON to wholesale or distribute the Products on an arms-length basis to Third Parties in the Territory.",
          "bbox": [
            277.0,
            1191.0,
            3029.0,
            1237.0
          ],
          "confidence": 0.9940798282623291
        },
        {
          "text": "(\"Gross Sales\"), less (as applicable) the following ETON expenses as accrued and adjusted for amounts actually taken, consistent with ETON'S",
          "bbox": [
            277.0,
            1248.0,
            3029.0,
            1292.0
          ],
          "confidence": 0.9855876564979553
        },
        {
          "text": "standard accounting practices in accordance with GAAP: (a) amounts refunded or credited for returned, damaged, outdated, short-dated or",
          "bbox": [
            277.0,
            1308.0,
            3027.0,
            1352.0
          ],
          "confidence": 0.995091438293457
        },
        {
          "text": "defective goods, and bad debts, and (b) all of the following: (i) taxes, duties and other governmental charges related to the production, use or sale",
          "bbox": [
            279.0,
            1367.0,
            3029.0,
            1409.0
          ],
          "confidence": 0.9986030459403992
        },
        {
          "text": "of the Products (including, including without limitation the brand manufacturer's tax imposed pursuant to the Patient Protection and Affordable.",
          "bbox": [
            275.0,
            1420.0,
            3029.0,
            1466.0
          ],
          "confidence": 0.9934532642364502
        },
        {
          "text": "Care Act (Pub. L. No. 111-148) as amended or replaced, but not including taxes assessed against the income derived from such sale); (ii) trade,",
          "bbox": [
            279.0,
            1478.0,
            3025.0,
            1520.0
          ],
          "confidence": 0.9948992729187012
        },
        {
          "text": "quantity and cash discounts, allowances, retroactive price adjustments, credit incentive payments, chargebacks, patient support programs, and",
          "bbox": [
            281.0,
            1535.0,
            3029.0,
            1579.0
          ],
          "confidence": 0.998204231262207
        },
        {
          "text": "rebates (including governmental rebates or other price reductions provided, based on sales by ETON to any Governmental Entity or regulatory.",
          "bbox": [
            275.0,
            1590.0,
            3025.0,
            1635.0
          ],
          "confidence": 0.9933704733848572
        },
        {
          "text": "authority in respect of state or federal Medicare, Medicaid, government pricing or similar programs;); and (iii) any costs incurred in connection with.",
          "bbox": [
            277.0,
            1645.0,
            3029.0,
            1690.0
          ],
          "confidence": 0.9868744015693665
        },
        {
          "text": "or arising out of compliance with any Risk Evaluation and Mitigation Strategies approved by the FDA and (iv) any expenses associated with",
          "bbox": [
            279.0,
            1703.0,
            3025.0,
            1747.0
          ],
          "confidence": 0.9935091137886047
        },
        {
          "text": "serialization of the Products. Distribution of Licensed Products for clinical trials or as samples will not be deemed a \"Net Sale\"' under this definition.",
          "bbox": [
            276.0,
            1758.0,
            3014.0,
            1800.0
          ],
          "confidence": 0.983973503112793
        },
        {
          "text": "3",
          "bbox": [
            1642.0,
            1815.0,
            1673.0,
            1855.0
          ],
          "confidence": 0.9959298968315125
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975345134735107
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 2,
          "bbox": [
            2701.0,
            256.0,
            3025.0,
            292.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "After termination is effective and Aucta assumes control of the Product, ETON will provide, to the extent practicable, transition services to Aucta to include assistance with Product distribution, processing of rebates, drug safety, etc. at Aucta's cost for such services, for a reasonable period of time as mutually determined by the Parties but not to exceed one hundred eighty (180) days following termination so that Aucta can get its own such services in place.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "After termination is effective and Aucta assumes control of the Product, ETON will provide, to the extent practicable, transition services to Aucta to include assistance with Product distribution, processing of rebates, drug safety, etc. at Aucta's cost for such services, for a reasonable period of time as mutually determined by the Parties but not to exceed one hundred eighty (180) days following termination so that Aucta can get its own such services in place.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "If this Agreement is terminated by Aucta under Section 11.2 or 11.3, then (a) ETON shall have the right to, and Aucta shall hereby grant ETON a license to, Market or otherwise dispose of any existing inventory of any Products then in ETON's possession subject to paying all Royalties and other amounts due hereunder for such sales, (b) Aucta may keep all the payments under Section 6 paid by ETON up to the point of termination and for ETON's disposal of remaining inventory and Aucta is free to commercialize or relicense the Product with no further obligations owed to ETON, (c) ETON shall refrain from holding itself out as Aucta's distributor, in particular, eliminate any reference to the Product and Aucta from its business, trade style and promotional material, and (d) ETON shall transfer all rights, licenses within thirty (30) days of termination.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "If this Agreement is terminated by Aucta under Section 11.2 or 11.3, then (a) ETON shall have the right to, and Aucta shall hereby grant ETON a license to, Market or otherwise dispose of any existing inventory of any Products then in ETON's possession subject to paying all Royalties and other amounts due hereunder for such sales, (b) Aucta may keep all the payments under Section 6 paid by ETON up to the point of termination and for ETON's disposal of remaining inventory and Aucta is free to commercialize or relicense the Product with no further obligations owed to ETON, (c) ETON shall refrain from holding itself out as Aucta's distributor, in particular, eliminate any reference to the Product and Aucta from its business, trade style and promotional material, and (d) ETON shall transfer all rights, licenses within thirty (30) days of termination.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Each Party shall permit an independent certified public accounting firm selected by the auditing Party and reasonably acceptable to the non-auditing Party, that has agreed to be bound by a confidentiality agreement reasonably acceptable to the Parties, to have access, during normal business hours and upon reasonable prior notice (not more often than once in any calendar year), to those books and records maintained by the non-auditing Party necessary for the auditing Party to verify the accuracy of the non-auditing Party's calculations under this Section 6 and/or cost of Product(s) for any period ending not more than two (2) years prior to the date of such request, subject to any limitations in scope necessary to comply with Applicable Law, Third Party confidentiality restrictions, or maintain legal privilege, including but not limited to Third Party pricing information.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Each Party shall permit an independent certified public accounting firm selected by the auditing Party and reasonably acceptable to the non-auditing Party, that has agreed to be bound by a confidentiality agreement reasonably acceptable to the Parties, to have access, during normal business hours and upon reasonable prior notice (not more often than once in any calendar year), to those books and records maintained by the non-auditing Party necessary for the auditing Party to verify the accuracy of the non-auditing Party's calculations under this Section 6 and/or cost of Product(s) for any period ending not more than two (2) years prior to the date of such request, subject to any limitations in scope necessary to comply with Applicable Law, Third Party confidentiality restrictions, or maintain legal privilege, including but not limited to Third Party pricing information.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Cap On Liability_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, NEITHER PARTY SHALL BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES, WHETHER FORESEEABLE OR NOT, THAT ARE IN ANY WAY RELATED TO THIS AGREEMENT.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Cap On Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, NEITHER PARTY SHALL BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES, WHETHER FORESEEABLE OR NOT, THAT ARE IN ANY WAY RELATED TO THIS AGREEMENT.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Insurance_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "At all times from the first commercial sale of any Product(s) or after the Effective Date through the date which is five (5) years after the final sale of such Product(s), the Parties will maintain general liability insurance in amounts that are reasonable and customary in the pharmaceutical industry, provided in no event shall the general liability insurance amounts be less than five million dollars ($5,000,000) per occurrence and ten million dollars ($10,000,000) in the aggregate limit of liability per year.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            285.0,
            3025.0,
            323.0
          ],
          "confidence": 0.9644784927368164
        },
        {
          "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
          "bbox": [
            314.0,
            338.0,
            2992.0,
            382.0
          ],
          "confidence": 0.9847054481506348
        },
        {
          "text": "competitively harmful if publicly disclosed.",
          "bbox": [
            1247.0,
            398.0,
            2057.0,
            439.0
          ],
          "confidence": 0.9998692870140076
        },
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ],
          "confidence": 0.9987989664077759
        },
        {
          "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
          "bbox": [
            444.0,
            506.0,
            3027.0,
            552.0
          ],
          "confidence": 0.9820212125778198
        },
        {
          "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
          "bbox": [
            279.0,
            568.0,
            3025.0,
            610.0
          ],
          "confidence": 0.9877843856811523
        },
        {
          "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
          "bbox": [
            279.0,
            627.0,
            3021.0,
            672.0
          ],
          "confidence": 0.9800608158111572
        },
        {
          "text": "RECITALS",
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ],
          "confidence": 0.9993770718574524
        },
        {
          "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
          "bbox": [
            444.0,
            740.0,
            3007.0,
            791.0
          ],
          "confidence": 0.9852975010871887
        },
        {
          "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
          "bbox": [
            446.0,
            799.0,
            2876.0,
            844.0
          ],
          "confidence": 0.9869436621665955
        },
        {
          "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
          "bbox": [
            448.0,
            857.0,
            3030.0,
            899.0
          ],
          "confidence": 0.9932822585105896
        },
        {
          "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
          "bbox": [
            279.0,
            914.0,
            3029.0,
            956.0
          ],
          "confidence": 0.9994465708732605
        },
        {
          "text": "and conditions set forth herein;.",
          "bbox": [
            277.0,
            968.0,
            868.0,
            1011.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
          "bbox": [
            442.0,
            1020.0,
            3031.0,
            1071.0
          ],
          "confidence": 0.9927972555160522
        },
        {
          "text": "the terms and conditions set forth herein: and.",
          "bbox": [
            279.0,
            1082.0,
            1127.0,
            1118.0
          ],
          "confidence": 0.9909569621086121
        },
        {
          "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
          "bbox": [
            448.0,
            1137.0,
            3027.0,
            1180.0
          ],
          "confidence": 0.9947659969329834
        },
        {
          "text": "Date (later defined) occurs..",
          "bbox": [
            281.0,
            1197.0,
            783.0,
            1233.0
          ],
          "confidence": 0.9870816469192505
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
          "bbox": [
            442.0,
            1248.0,
            3025.0,
            1292.0
          ],
          "confidence": 0.9929294586181641
        },
        {
          "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
          "bbox": [
            275.0,
            1303.0,
            3027.0,
            1350.0
          ],
          "confidence": 0.9988505840301514
        },
        {
          "text": "to be legally bound, hereby agree as follows:",
          "bbox": [
            279.0,
            1363.0,
            1113.0,
            1405.0
          ],
          "confidence": 0.9942082762718201
        },
        {
          "text": "1. DEFINITIONS.",
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ],
          "confidence": 0.9909024834632874
        },
        {
          "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
          "bbox": [
            446.0,
            1475.0,
            3018.0,
            1517.0
          ],
          "confidence": 0.9979770183563232
        },
        {
          "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
          "bbox": [
            448.0,
            1531.0,
            3027.0,
            1575.0
          ],
          "confidence": 0.9903261661529541
        },
        {
          "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
          "bbox": [
            281.0,
            1592.0,
            3027.0,
            1634.0
          ],
          "confidence": 0.9860179424285889
        },
        {
          "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
          "bbox": [
            281.0,
            1648.0,
            1880.0,
            1690.0
          ],
          "confidence": 0.9866490960121155
        },
        {
          "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
          "bbox": [
            446.0,
            1703.0,
            2342.0,
            1745.0
          ],
          "confidence": 0.9826157689094543
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975879192352295
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            962.0,
            451.0,
            2345.0,
            495.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1546.0,
            689.0,
            1762.0,
            725.0
          ]
        },
        {
          "text": "1. DEFINITIONS.",
          "page": 0,
          "bbox": [
            281.0,
            1420.0,
            609.0,
            1456.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "At all times from the first commercial sale of any Product(s) or after the Effective Date through the date which is five (5) years after the final sale of such Product(s), the Parties will maintain general liability insurance in amounts that are reasonable and customary in the pharmaceutical industry, provided in no event shall the general liability insurance amounts be less than five million dollars ($5,000,000) per occurrence and ten million dollars ($10,000,000) in the aggregate limit of liability per year.",
      "page_number": 1,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9995815753936768
        },
        {
          "text": "1.3 \"Applicable Law\" means the applicable laws, rules, regulations, guidelines and requirements of any Governmental Entity related to the",
          "bbox": [
            446.0,
            311.0,
            3027.0,
            356.0
          ],
          "confidence": 0.992168128490448
        },
        {
          "text": "development, registration, manufacture, importation, commercialization of the Products in the Territory, the manufacture in and export from the",
          "bbox": [
            279.0,
            375.0,
            3027.0,
            417.0
          ],
          "confidence": 0.9982569813728333
        },
        {
          "text": "Territory of Manufacture, or any obligation under, or related to, this Agreement, including those obligations applicable to the Dossiers.",
          "bbox": [
            275.0,
            428.0,
            2789.0,
            471.0
          ],
          "confidence": 0.9933432936668396
        },
        {
          "text": "1.4 \"Aucta Background Intellectual Property\"' means any and all patents and trademarks, patent and trademark applications or other",
          "bbox": [
            446.0,
            486.0,
            3029.0,
            528.0
          ],
          "confidence": 0.9944490790367126
        },
        {
          "text": "patent and trademark rights, copyrights, inventions, know-how, trade secrets, proprietary knowledge, data, formulations, product specifications and",
          "bbox": [
            277.0,
            546.0,
            3029.0,
            588.0
          ],
          "confidence": 0.990257203578949
        },
        {
          "text": "other information owned, licensed to or controlled by Aucta relating to the Products, including but not limited to use, manufacture, and packaging.",
          "bbox": [
            274.0,
            594.0,
            3029.0,
            651.0
          ],
          "confidence": 0.9948107600212097
        },
        {
          "text": "thereof.",
          "bbox": [
            276.0,
            654.0,
            424.0,
            698.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "1.5 \"Aucta Indemnified Parties\"' shall have the meaning ascribed to the term in Section 13.2 of this Agreement..",
          "bbox": [
            448.0,
            711.0,
            2514.0,
            755.0
          ],
          "confidence": 0.9912346601486206
        },
        {
          "text": "1.6 \"Breaching Party\"' shall have the meaning ascribed to the term in Section 11.2 of this Agreement.",
          "bbox": [
            448.0,
            773.0,
            2322.0,
            815.0
          ],
          "confidence": 0.9945749640464783
        },
        {
          "text": "1.7 \"Business Day\"' means any day, other than Saturday, Sunday or other day on which commercial banks are authorized or required to",
          "bbox": [
            446.0,
            830.0,
            3025.0,
            875.0
          ],
          "confidence": 0.9902889132499695
        },
        {
          "text": "close in New York, New York or Rome, Italy.",
          "bbox": [
            277.0,
            890.0,
            1086.0,
            936.0
          ],
          "confidence": 0.9996263980865479
        },
        {
          "text": "1.9 \"Claim\" includes a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award.",
          "bbox": [
            446.0,
            1005.0,
            3023.0,
            1053.0
          ],
          "confidence": 0.9879875183105469
        },
        {
          "text": "damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract,",
          "bbox": [
            279.0,
            1069.0,
            3029.0,
            1111.0
          ],
          "confidence": 0.9883736371994019
        },
        {
          "text": "tort or statute and whether involving a Third Party or a Party or otherwise.",
          "bbox": [
            279.0,
            1127.0,
            1658.0,
            1164.0
          ],
          "confidence": 0.9934023022651672
        },
        {
          "text": "1.10 \"Confidential Information' shall have the meaning ascribed to the term in Section 9.2 of this Agreement.",
          "bbox": [
            448.0,
            1180.0,
            2496.0,
            1222.0
          ],
          "confidence": 0.987881064414978
        },
        {
          "text": "the Products as set forth in Exhibit A.",
          "bbox": [
            281.0,
            1301.0,
            975.0,
            1338.0
          ],
          "confidence": 0.995679497718811
        },
        {
          "text": "1.12 \"Effective Date\"' shall have the meaning ascribed to the term in Section 11.1 of this Agreement.",
          "bbox": [
            446.0,
            1356.0,
            2296.0,
            1398.0
          ],
          "confidence": 0.9820043444633484
        },
        {
          "text": "1.13 \"ETON Indemnified Parties\" shall have the meaning ascribed to the term in Section 13.1 of this Agreement..",
          "bbox": [
            446.0,
            1413.0,
            2539.0,
            1458.0
          ],
          "confidence": 0.9862416982650757
        },
        {
          "text": "1.14 \"FDA\" means the United States Food and Drug Administration and all divisions under its direct control or any successor",
          "bbox": [
            448.0,
            1475.0,
            3030.0,
            1517.0
          ],
          "confidence": 0.9951766133308411
        },
        {
          "text": "organizations",
          "bbox": [
            281.0,
            1537.0,
            533.0,
            1575.0
          ],
          "confidence": 0.9954598546028137
        },
        {
          "text": "1.15 \"Force Majeure Events\"' shall have the meaning ascribed to such term in Section 15.2 of this Agreement.",
          "bbox": [
            448.0,
            1590.0,
            2487.0,
            1632.0
          ],
          "confidence": 0.9897738695144653
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1652.0,
            1673.0,
            1690.0
          ],
          "confidence": 0.9925864338874817
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9977135062217712
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 1,
          "bbox": [
            2702.0,
            258.0,
            3025.0,
            294.0
          ]
        }
      ]
    },
    {
      "id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement__Insurance_2",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "The Parties shall provide written proof of such insurance to each other upon request.",
      "page_number": 2,
      "words": [
        {
          "text": "CONFIDENTIAL",
          "bbox": [
            2701.0,
            256.0,
            3025.0,
            292.0
          ],
          "confidence": 0.9953160881996155
        },
        {
          "text": "1.16 \"GMP\"' means current good manufacturing practices as defined by the FDA..",
          "bbox": [
            448.0,
            311.0,
            1956.0,
            353.0
          ],
          "confidence": 0.9857128858566284
        },
        {
          "text": "1.17 \"Governmental Entity\"' means any arbitrator, court, judicial, legislative, administrative, or regulatory agency, commission, department,.",
          "bbox": [
            446.0,
            371.0,
            3029.0,
            418.0
          ],
          "confidence": 0.985506534576416
        },
        {
          "text": "board, or bureau or body or other government authority or instrumentality or any Person or entity exercising executive, legislative, judicial,",
          "bbox": [
            275.0,
            431.0,
            3027.0,
            475.0
          ],
          "confidence": 0.9825104475021362
        },
        {
          "text": "regulatory, or administrative functions of or pertaining to government, whether foreign or domestic, whether federal, state, provincial, municipal, or.",
          "bbox": [
            279.0,
            490.0,
            3029.0,
            534.0
          ],
          "confidence": 0.9963580965995789
        },
        {
          "text": "Other.",
          "bbox": [
            275.0,
            545.0,
            382.0,
            583.0
          ],
          "confidence": 0.9671776294708252
        },
        {
          "text": "1.18 \"Gross Sales\"' shall have the meaning ascribed to the term in Section 1.26.",
          "bbox": [
            446.0,
            598.0,
            1900.0,
            643.0
          ],
          "confidence": 0.989698052406311
        },
        {
          "text": "1.19 \"Indemnitee' shall have the meaning ascribed to the term in Section 13.3.1 of this Agreement..",
          "bbox": [
            446.0,
            658.0,
            2275.0,
            704.0
          ],
          "confidence": 0.9839974045753479
        },
        {
          "text": "1.20 \"Indemnitor' shall have the meaning ascribed to the term in Section 13.3.1 of this Agreement..",
          "bbox": [
            448.0,
            720.0,
            2275.0,
            762.0
          ],
          "confidence": 0.9868714213371277
        },
        {
          "text": "1.21 \"Infringement Notification Date\" shall have the meaning ascribed to the term in Section 7.4 of this Agreement..",
          "bbox": [
            448.0,
            780.0,
            2612.0,
            822.0
          ],
          "confidence": 0.9941144585609436
        },
        {
          "text": "1.22 \"Intellectual Rights Suit\" shall have the meaning ascribed to the term in Section 7.4 of this Agreement.",
          "bbox": [
            446.0,
            837.0,
            2461.0,
            883.0
          ],
          "confidence": 0.9914101958274841
        },
        {
          "text": "1.23 \"Losses\" means all losses, costs, damages, judgments, settlements, interest, fees or expenses including, without limitation, all.",
          "bbox": [
            444.0,
            894.0,
            3031.0,
            945.0
          ],
          "confidence": 0.9907868504524231
        },
        {
          "text": "reasonable attorneys' fees, experts' or consultants' fees, expenses and costs..",
          "bbox": [
            276.0,
            959.0,
            1711.0,
            1001.0
          ],
          "confidence": 0.9930619597434998
        },
        {
          "text": "1.24 \"Market' or \"Marketing\" shall have the meaning ascribed to the term in Section 2.1 of this Agreement.",
          "bbox": [
            446.0,
            1012.0,
            2456.0,
            1058.0
          ],
          "confidence": 0.9967002272605896
        },
        {
          "text": "1.25 \"NDC' means a national drug code as issued by the FDA..",
          "bbox": [
            446.0,
            1071.0,
            1615.0,
            1117.0
          ],
          "confidence": 0.9816356301307678
        },
        {
          "text": "1.26 \"Net Sales' means, with respect to each Product sold in the Territory, the aggregate gross sales amount invoiced by ETON or any.",
          "bbox": [
            442.0,
            1129.0,
            3029.0,
            1180.0
          ],
          "confidence": 0.9859305024147034
        },
        {
          "text": "sublicensee or other party authorized by ETON to wholesale or distribute the Products on an arms-length basis to Third Parties in the Territory.",
          "bbox": [
            277.0,
            1191.0,
            3029.0,
            1237.0
          ],
          "confidence": 0.9940798282623291
        },
        {
          "text": "(\"Gross Sales\"), less (as applicable) the following ETON expenses as accrued and adjusted for amounts actually taken, consistent with ETON'S",
          "bbox": [
            277.0,
            1248.0,
            3029.0,
            1292.0
          ],
          "confidence": 0.9855876564979553
        },
        {
          "text": "standard accounting practices in accordance with GAAP: (a) amounts refunded or credited for returned, damaged, outdated, short-dated or",
          "bbox": [
            277.0,
            1308.0,
            3027.0,
            1352.0
          ],
          "confidence": 0.995091438293457
        },
        {
          "text": "defective goods, and bad debts, and (b) all of the following: (i) taxes, duties and other governmental charges related to the production, use or sale",
          "bbox": [
            279.0,
            1367.0,
            3029.0,
            1409.0
          ],
          "confidence": 0.9986030459403992
        },
        {
          "text": "of the Products (including, including without limitation the brand manufacturer's tax imposed pursuant to the Patient Protection and Affordable.",
          "bbox": [
            275.0,
            1420.0,
            3029.0,
            1466.0
          ],
          "confidence": 0.9934532642364502
        },
        {
          "text": "Care Act (Pub. L. No. 111-148) as amended or replaced, but not including taxes assessed against the income derived from such sale); (ii) trade,",
          "bbox": [
            279.0,
            1478.0,
            3025.0,
            1520.0
          ],
          "confidence": 0.9948992729187012
        },
        {
          "text": "quantity and cash discounts, allowances, retroactive price adjustments, credit incentive payments, chargebacks, patient support programs, and",
          "bbox": [
            281.0,
            1535.0,
            3029.0,
            1579.0
          ],
          "confidence": 0.998204231262207
        },
        {
          "text": "rebates (including governmental rebates or other price reductions provided, based on sales by ETON to any Governmental Entity or regulatory.",
          "bbox": [
            275.0,
            1590.0,
            3025.0,
            1635.0
          ],
          "confidence": 0.9933704733848572
        },
        {
          "text": "authority in respect of state or federal Medicare, Medicaid, government pricing or similar programs;); and (iii) any costs incurred in connection with.",
          "bbox": [
            277.0,
            1645.0,
            3029.0,
            1690.0
          ],
          "confidence": 0.9868744015693665
        },
        {
          "text": "or arising out of compliance with any Risk Evaluation and Mitigation Strategies approved by the FDA and (iv) any expenses associated with",
          "bbox": [
            279.0,
            1703.0,
            3025.0,
            1747.0
          ],
          "confidence": 0.9935091137886047
        },
        {
          "text": "serialization of the Products. Distribution of Licensed Products for clinical trials or as samples will not be deemed a \"Net Sale\"' under this definition.",
          "bbox": [
            276.0,
            1758.0,
            3014.0,
            1800.0
          ],
          "confidence": 0.983973503112793
        },
        {
          "text": "3",
          "bbox": [
            1642.0,
            1815.0,
            1673.0,
            1855.0
          ],
          "confidence": 0.9959298968315125
        },
        {
          "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9975345134735107
        }
      ],
      "nearby_headers": [
        {
          "text": "CONFIDENTIAL",
          "page": 2,
          "bbox": [
            2701.0,
            256.0,
            3025.0,
            292.0
          ]
        }
      ]
    }
  ]
}